What's breaking now, across thousands of outlets.
Viking's weight loss pill program has a couple of issues, including the fierce competitors who have a big head start.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
Bristol Myers Squibb trades at a steeper discount despite higher leverage, while Novo Nordisk commands a premium on exceptional profitability and GLP-1 dominance.
Key PointsThe director acquired 2,000 shares at $28.27 per share for a total transaction value of $56,540.
The LEO satellite developer still has plenty of upside potential.
BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.
Bloomberg Intelligence Senior Insurance Equity Analyst Matthew Palazola tells Bloomberg This Weekend that Hurricane Isaias could generate insured losses in the single-digit billions of dollars, with…
Key PointsExxonMobil CEO Darren Woods famously called Venezuela “uninvestable.”